<DOC>
	<DOC>NCT02475330</DOC>
	<brief_summary>This single arm Phase II trial will investigate the feasibility of dietary flaxseed (FS) supplementation in subjects receiving definitive chemoradiotherapy for non-small cell lung cancer (NSCLC). Subjects will ingest FS for a period of approximately 8 to 9 weeks during the course of radiation treatment. Study participation and surveillance will last approximately 6 months. Subject specimen collection will include: blood, urine, and buccal swabs at 5 time points.</brief_summary>
	<brief_title>Dietary Flaxseed in NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Male or female, ages 18 and older Current diagnosis of nonsmall cell lung cancer (NSCLC) including patients who have metastatic disease requiring definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy. Able to provide written informed consent and comply with all study procedures Total planned radiation dose to gross disease 6070 Gy. Current diagnosis of disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication (history of major gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis, or gastrointestinal bleeding) Known hypersensitivity to flaxseed or any of its metabolites, or wheat products Taking or has taken an investigational drug within 14 days. Taking or has taken Amifostine or Mucomyst (Nacetylcysteine) within 14 days Current or prior use of flaxseed, flaxcontaining products, soybeans, or soycontaining products Current or prior use (limited to prior 14 days) of dietary supplements such as herbals or botanicals Prior thoracic and/or mediastinal radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>